Bopindolol for the treatment of chronic stable angina pectoris--a clinical study of the relationship between dose and effect.

Following a 4-week placebo period, 19 patients (12 male, average age 62.3 years) with chronic stable angina pectoris and a positive exercise test were treated with the beta-adrenoceptor antagonists bopindolol at increasing doses of 0.5, 1 and 2 mg, each being given once daily for 4 weeks. For the final 4 weeks of the study, active treatment was replaced by placebo. Maximum tolerated exercise (bicycle ergometry, performed 24 h after drug administration) increased dose-dependently from 519 +/- 59 s (baseline) to 758 +/- 95 s with 2 mg (p less than 0.001) and fell again to 508 +/- 48 s (placebo). The frequency of anginal attacks also fell dose-dependently from an average of 5.4 per week (baseline) to 0.5 with 2 mg (p less than 0.001) and rose again to 5.1 per week when active treatment was stopped.

RCT Entities:   Population Interventions Outcomes